Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

At LT follow-up, median OS was unchanged, but at later time-points the tails of the Oral-AZA and placebo OS curves showed greater separation, indicating sustained LT OS benefit with Oral-AZA. Intermediate-risk cytogenetics and NPM1 at diagnosis, and absence of post-IC MRD, were associated with LT survival.